Blogs
Advertisement
The somewhat-awkwardly named TransCelerate BioPharma immediately got an enthusiastic reception from industry watchers and participants, mainly due to the perception that it was well poised to attack some of the systemic causes of delays and cost overruns that plague clinical trials today.
Advertisement
Advertisement
An entire section of Horizon 2020 is devoted to health, demographic change, and well-being.
Clinical trials community reacts favorably to tentative set of new rules, yet questions remain.
Proposed rule changes on public information in Europe never make it to fruition.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials' 2025 State of the Industry Survey
2
Establishing Governance for No-Code AI in Clinical Operations
3
The Confidence Trap in Clinical Trials: When Knowing Just Enough Becomes Dangerous
4
Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
